NCT03792516View on ClinicalTrials.gov

Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

December 3, 2024

Conditions
Vulvar DysplasiaHPV-Related Vulvar Intraepithelial NeoplasiaPreinvasive Vulvar DiseaseVulva Intraepithelial NeoplasiaVulvar Diseases
Interventions
DRUG

artesunate ointment 40%

artesunate formulated as an ointment to be applied topically to the vulva

Trial Locations (4)

21205

Johns Hopkins Outpatient Center, Baltimore

44111

Cleveland Clinic Fairview Hospital, Cleveland

44124

Cleveland Clinic - Hillcrest Hospital, Mayfield Heights

44195

Cleveland Clinic Foundation - Main Campus, Cleveland

Sponsors
All Listed Sponsors
collaborator

Frantz Viral Therapeutics, LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03792516 - Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3) | Biotech Hunter | Biotech Hunter